



THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder Collaboration to Advance Oncology Therapeutics.





WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a non-profit organisation registered in Belgium that provides a neutral platform to stimulate interaction between stakeholders involved in cancer drug development.

OUR MISSION

The CDDF's mission is to facilitate collaboration between stakeholders, to increase efficiency in cancer drug development and accelerate the delivery of effective oncology treatment to patients.

• HOW WE ADVANCE OUR MISSION

- The CDDF provides a non-competitive, non-commercial platform for multi-stakeholder discussions and collaboration
- The CDDF brings together all actors in the oncology community such as academia, the healthcare industry, regulatory authorities, HTAs, policymakers and patient advocacy groups
- The CDDF stimulates advancement and innovation in the field through scientific debate and open discussion



INITIATIVES

For many years, the Cancer Drug Development Forum (CDDF) has stimulated discussions to accelerate effective drug development in oncology treatment and shorten time to market, and time to patient access.

The CDDF offers workshops, conferences and webinars that bring stakeholders involved in cancer drug development into a productive dialogue in a neutral, non-competitive space.

The association drives multiple activities and initiatives in **close contact with regulators** from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and national regulatory agencies, **HTAs**, **academic researchers** from around the globe, **healthcare companies**, and **patient advocates**.





FACILITATE. DEBATE. ACTIVATE. INNOVATE.

The Cancer Drug Development Forum (CDDF) **Annual Conference** is a unique meeting which facilitates open, meaningful dialogue. This multi-stakeholder, interactive three-day gathering offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The agile, responsive nature of the CDDF platform allows **programs to be quickly initiated or adapted to reflect current and pressing issues**. The CDDF has also clearly proved to be a **visionary force within the cancer drug development field** addressing topics such as immuno-oncology, real-world data in cancer drug development, histology independent drug development and MRT & ctDNA in oncology, diversity in oncology clinical trials and the combination of immunotherapy and radiotherapy.

The CDDF continues to **pioneer progress in cancer drug treatments** through workshops and webinars exploring topics affecting the future of cancer care, such as real-world evidence, decentralised care and trials, drug and biomarker combinations, clinical research in Central and Eastern Europe and innovation in rare cancers.

The association also publishes executive summaries, white papers and meeting reports from workshops discussions, conference presentations and lecture briefings in order to increase knowledge of the challenges and opportunities in cancer drug development.



CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAS, THE INDUSTRY,
ACADEMICS AND PATIENT
ADVOCATES TO
COLLABORATE

COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT

CDDF LEADERSHIP



The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs, representing a range of perspectives within the drug development process.

These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statistician, regulatory scientists, and pharmacists who have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS



Ruth Plummer Chairperson



Symeonides
Vice-Chairperson



Glasmacher
Treasurer



VerweijManaging Director



Catarina Edfjaëll



Mark Lawler



Eva Skolvlund



Rosa Giuliani



Christian Schneider



Fergus Sweeney

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.



Marjorie Recorbet Director of Operations




Giorgia Campagnano **Event Manager**



Caroline Marissal **Event Coordinator**



Hyunmin Park Community & Communication Coordinator



CDDF ACTIVITIES 2024



Click the buttons to view detailed information

MULTI-STAKEHOLDER DISCUSSIONS





<u>Programme</u> <u>Executive</u> <u>summary</u>







<u>Programme</u>

<u>Registration</u>

CDDF ACTIVITIES 2024



CDDF WEBINAR SERIES



LIVE WEBINAR

COVID-19 and Cancer: Time for a Reset to Repair the Damage Done

> Ajay Aggarwal (The London School of Hygiene and Tropical Medicine) & Debbie Keatley (Cancer Research UK)

15 January 2024 17:00-18:00 CET, Online

Recording/slides



<u>Takeaways</u>



Recording/slides

<u>Takeaways</u>



LIVE WEBINAR

Cancer Medicines Forum:

Advancing Cancer Treatment Optimization Across Europe

Denis Lacombe (EORTC, BE)

25 June 2024 16:00-17:00 CEST, Online



<u>Takeaways</u>



LIVE WEBINAR

Bayesian Approaches in Drug Development

> Robert Hemmings (CONSILIUM Salmonson & Hemmings)

11 July 2024 17:00-18:00 CEST, Online

Recording/slides



Takeaways





LIVE WEBINAR SERIES

Al and Big Data Al in cancer drug development

An introduction to the use of Al in cancer drug development and regulatory considerations

Dr Katrin Rupalla (Johnson & Johnson)

29 October 2024 17:00-18:00 CET, Online



Registration



LIVE WEBINAR

EU Clinical Trial Regulations

Stephanie Kromar (EORTC)

Dr Tarec Christoffer El-Galaly (Aarhus University)

12 November 2024 17:00-18:00 CET, Online



Registration

MEETING OUTCOMES 2023

Click the buttons to view meeting outputs

CDDF Annual Conference 2023: Challenges in Clinical Trial Performance (6 – 8 February 2023, NL)

Executive summary

Meeting report

Recordings/slides

Multi-Stakeholder Workshop: Dose Optimisation in Early Oncology Drug Development (3 – 4 April 2023, NL)

Executive summary

White paper (available soon)

Recordings/slides (member only*)

Multi-Stakeholder Workshop: Innovative Oncology Trial Designs (18 - 19 September 2023, NL)

Executive summary

White paper (available soon)

Recordings/slides (member only*)

Multi-Stakeholder Workshop: The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology (13-14 November 2023, NL)

<u>Executive</u> summary

White paper

Recordings/slides (member only*)

*Recent meeting recordings and slides are accessible exclusively to the CDDF Industry Members, the CDDF Full Association Member, Patient Advocates, HTAs, and regulators (FDA, EMA, HTAs and national agencies) for educational purposes

MEETING OUTCOMES 2023

Click the buttons to view meeting outputs

CDDF Live Webinar:

Immunotherapy and Radiotherapy Combinations Part 2: Regulatory Considerations

(27 February 2023)

<u>Key takeaways</u>

Recordings/slides

CDDF Live Webinar:

Development of Novel and Targeted Agents in Precision Cancer Prevention and Interception (15 June 2023)

<u>Key takeaways</u>

Recordings/slides

CDDF Live Webinar:

Beating Cancer In Europe - Time to Deliver

(10 July 2023)

Key takeaways

Recordings/slides

CDDF Live Webinar:

Critical Impacts of the In Vitro
Diagnostic Regulation (IVDR)
Implementation on Patient Access
to Clinical Trials

(7 September 2023)

<u>Key takeaways</u>

Recordings/slides

CDDF Live Webinar:

Perspectives on the New EU
Health Technology Assessment
(HTA) Regulation 2021/2282

(28 September 2023)

Key takeaways

Recordings/slides

CDDF ACTIVITIES 2025


➤ ANNUAL CONFERENCE 2025 (HYBRID)
Challenges, Advances, and Open Questions in
Global Cancer Drug Development and Clinical
Trials

(3 – 5 Feb 2025, Noordwijk aan Zee, NL)

- MULTI-STAKEHOLDER WORKSHOP (HYBRID)
 New Modalities in Cancer Drug Development
 (31 Mar 1 Apr 2025, Brussels, BE)
- MULTI-STAKEHOLDER WORKSHOP (HYBRID)
 Accelerating Drug Development to Deliver Better
 Patient Care
 (17 18 Nov 2025, Brussels, BE)
- ➤ AAADV-ASCO-CDDF Workshop
 Global Oncology Drug Development
 (early May 2025, Washington, D.C., US)



Visit the CDDF website to stay informed about upcoming multi-stakeholder discussions



COLLABORATION AND OPEN DIALOGUE AMONG ALL STAKEHOLDERS ARE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS









in The Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752